SCHEMBL3374111

SCHEMBL3374111

CS(=O)(=O)Nc1ccc(-c2cc(F)cc(F)c2)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.50
HPGD P15428 1/20 0.50
MAPK1 P28482 1/20 0.50
KIF11 P52732 3/20 0.46
BRD4 O60885 1/20 0.46
CYP17A1 P05093 2/20 0.46
GRIN1 Q05586 2/20 0.41
KCNH2 Q12809 2/20 0.41
GRIN2B Q13224 2/20 0.41
HSD17B3 P37058 1/20 0.40
HSD17B2 P37059 1/20 0.40
AURKA O14965 1/20 0.40
KDR P35968 1/20 0.40
AURKB Q96GD4 1/20 0.40
PGR P06401 1/20 0.40
MET P08581 1/20 0.40
KIT P10721 1/20 0.40
HAVCR2 Q8TDQ0 2/20 0.40
EPHX2 P34913 1/20 0.40
NR1H4 Q96RI1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3378764 0.88 PTGS2 (0.51) GAAHPGDMAPK1KIF11CYP17A1
SCHEMBL3378891 0.87 SLC22A12 (0.52) GAAHPGDMAPK1KIF11BRD4
SCHEMBL3379785 0.87 GAA (0.49) GAAHPGDMAPK1KIF11CYP17A1
SCHEMBL3375774 0.84 GAA (0.52) GAAHPGDMAPK1KIF11BRD4
SCHEMBL3374747 0.82 KIF11 (0.51) GAAHPGDMAPK1KIF11CYP17A1
SCHEMBL3377083 0.82 PTGS2 (0.52) GAAHPGDMAPK1KIF11CYP17A1
SCHEMBL3376954 0.82 KIF11 (0.48) GAAHPGDMAPK1KIF11CYP17A1
SCHEMBL3378931 0.81 KIF11 (0.67) GAAHPGDMAPK1KIF11CYP17A1
SCHEMBL3375693 0.81 KIF11 (0.54) GAAHPGDMAPK1KIF11BRD4
SCHEMBL3377007 0.81 KIT (0.51) GAAHPGDMAPK1KIF11BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 GAA 1564/4885HPGD 633/4885MAPK1 1122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.